Clin2
NCT07369115Worth exploringNot yet recruiting

Adding lumateperone for depression after early-life trauma

Major Depressive DiorderEarly Life Trauma

Treatments studied

Part of Mental health clinical trials.

This trial tests whether adding a medication called lumateperone to your current antidepressant helps depression in people who experienced early-life trauma. It also uses brain scans to understand how the treatment works.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
50 people
Ages
21 years to 70 years
Study type
Interventional

Who can take part

  • You must be between 21 and 70 years old.
  • You must have a diagnosis of major depression (without psychosis).
  • You must have experienced physical or sexual assault before age 16.
  • You must have been on a stable antidepressant for at least 6 weeks without enough improvement.
  • You must be willing to have brain MRI scans.
  • You must not be at high risk for suicide or have certain medical conditions.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05850689Recruiting· Phase 3
Lumateperone add-on for major depression that didn’t improve

This study tests whether adding lumateperone to an antidepressant helps adults with major depressive disorder (MDD) who haven’t improved enough after trying at least two different antidepressants. It may help reduce depressive symptoms more than antidepressants alone.

Huntsville, Alabama
NCT07623135Recruiting· Phase 3
Lumateperone for Hard-to-Treat Depression in Older Adults

This study tests lumateperone, a new medication added to your current antidepressant, to help treat depression that hasn't improved with other treatments. It's designed for people age 60 and older who have tried at least two antidepressants without success.

Tucson, Arizona
NCT07747389Not yet recruiting· Phase 3
Lumateperone vs placebo for major depressive disorder

This study tests a new medication (lumateperone) versus a placebo to see if it helps reduce symptoms of major depressive disorder. It is for people with moderate to severe depression who may be looking for a new treatment option.

NCT06372964Recruiting· Phase 3
Lumateperone for pediatric bipolar depression

This study tests a new medication called lumateperone for treating depression in children and teens with bipolar disorder. It aims to see if this drug can help improve mood and daily functioning.

Dothan, Alabama
NCT07699445Recruiting· Phase 4
Lumateperone for weight and mood in bipolar depression

This study tests if lumateperone, a medication for bipolar depression, can also help with weight and aging in people with obesity. You may qualify if you have bipolar I depression and a body mass index (BMI) over 30.

Boston, Massachusetts
NCT06482554Recruiting· Phase 3
Lumateperone for Apathy in Psychotic Disorders

This trial tests a medication called lumateperone to see if it can improve apathy (lack of motivation) in people who have psychotic symptoms from schizophrenia or related disorders. It may help if you are already on a stable treatment but still struggle with apathy.

Shreveport, Louisiana

Hear when a new Major Depressive Diorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.